Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
Top Cited Papers
Open Access
- 18 February 2015
- journal article
- review article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 36 (17), 1012-1022
- https://doi.org/10.1093/eurheartj/ehv043
Abstract
Statin-associated muscle symptoms (SAMS) are one of the principal reasons for statin non-adherence and/or discontinuation, contributing to adverse cardiovascular outcomes. This European Atherosclerosis Society (EAS) Consensus Panel overviews current understanding of the pathophysiology of statin-associated myopathy, and provides guidance for diagnosis and management of SAMS. Statin-associated myopathy, with significant elevation of serum creatine kinase (CK), is a rare but serious side effect of statins, affecting 1 per 1000 to 1 per 10 000 people on standard statin doses. Statin-associated muscle symptoms cover a broader range of clinical presentations, usually with normal or minimally elevated CK levels, with a prevalence of 7–29% in registries and observational studies. Preclinical studies show that statins decrease mitochondrial function, attenuate energy production, and alter muscle protein degradation, thereby providing a potential link between statins and muscle symptoms; controlled mechanistic and genetic studies in humans are necessary to further understanding. The Panel proposes to identify SAMS by symptoms typical of statin myalgia (i.e. muscle pain or aching) and their temporal association with discontinuation and response to repetitive statin re-challenge. In people with SAMS, the Panel recommends the use of a maximally tolerated statin dose combined with non-statin lipid-lowering therapies to attain recommended low-density lipoprotein cholesterol targets. The Panel recommends a structured work-up to identify individuals with clinically relevant SAMS generally to at least three different statins, so that they can be offered therapeutic regimens to satisfactorily address their cardiovascular risk. Further research into the underlying pathophysiological mechanisms may offer future therapeutic potential.Keywords
This publication has 116 references indexed in Scilit:
- Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant PatientsJAMA, 2012
- Effect of Coenzyme Q10 Supplementation on Statin-Induced MyalgiasThe American Journal of Cardiology, 2012
- Statin Use and Musculoskeletal Pain Among Adults With and Without ArthritisThe American Journal of Medicine, 2012
- Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL CholesterolJAMA, 2011
- Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathiesMolecular Genetics and Metabolism, 2011
- Mechanisms of statin-induced myalgia assessed by physiogenomic associationsAtherosclerosis, 2011
- Evaluation of skeletal muscle during calf exercise by 31‐phosphorus magnetic resonance spectroscopy in patients on statin medicationsMuscle & Nerve, 2010
- Effects of Combination Lipid Therapy in Type 2 Diabetes MellitusThe New England Journal of Medicine, 2010
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinThe New England Journal of Medicine, 2008
- The Role of Coenzyme Q10 in Statin-Associated Myopathy: A Systematic ReviewJournal of the American College of Cardiology, 2007